AT194769T - Use of nitric oxide-releasing compounds as a drug for strahlungssensibilisation for hypoxic cells - Google Patents

Use of nitric oxide-releasing compounds as a drug for strahlungssensibilisation for hypoxic cells

Info

Publication number
AT194769T
AT194769T AT94930608T AT94930608T AT194769T AT 194769 T AT194769 T AT 194769T AT 94930608 T AT94930608 T AT 94930608T AT 94930608 T AT94930608 T AT 94930608T AT 194769 T AT194769 T AT 194769T
Authority
AT
Austria
Prior art keywords
strahlungssensibilisation
drug
use
nitric oxide
releasing compounds
Prior art date
Application number
AT94930608T
Other languages
German (de)
Inventor
James B Mitchell
Angelo Russo
Murali C Krishna
David A Wink Jr
James E Liebmann
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13357493A priority Critical
Application filed by Us Health filed Critical Us Health
Priority to PCT/US1994/011306 priority patent/WO1995010267A1/en
Publication of AT194769T publication Critical patent/AT194769T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/131Amines acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/15Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • A61K38/063Glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
AT94930608T 1993-10-08 1994-10-07 Use of nitric oxide-releasing compounds as a drug for strahlungssensibilisation for hypoxic cells AT194769T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13357493A true 1993-10-08 1993-10-08
PCT/US1994/011306 WO1995010267A1 (en) 1993-10-08 1994-10-07 Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers

Publications (1)

Publication Number Publication Date
AT194769T true AT194769T (en) 2000-08-15

Family

ID=22459281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94930608T AT194769T (en) 1993-10-08 1994-10-07 Use of nitric oxide-releasing compounds as a drug for strahlungssensibilisation for hypoxic cells

Country Status (7)

Country Link
US (3) US5650442A (en)
EP (1) EP0722320B1 (en)
AT (1) AT194769T (en)
AU (1) AU685178B2 (en)
CA (1) CA2173738A1 (en)
DE (1) DE69425331D1 (en)
WO (1) WO1995010267A1 (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5691423A (en) * 1992-08-24 1997-11-25 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-bound nitric oxide-nucleophile adducts
US5840759A (en) * 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
AT194769T (en) * 1993-10-08 2000-08-15 Us Health Use of nitric oxide-releasing compounds as a drug for strahlungssensibilisation for hypoxic cells
US5726209A (en) * 1995-06-07 1998-03-10 Alliance Pharmaceutical Corp. Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
WO1998008496A1 (en) * 1996-08-27 1998-03-05 The University Of Akron Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
IL134696D0 (en) * 1997-08-26 2001-04-30 Technion Res & Dev Foundation Intravascular apparatus and method
US6159143A (en) * 1998-06-17 2000-12-12 Scimed Life Systems, Inc. Method and device for delivery of therapeutic agents in conjunction with isotope seed placement
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
CA2254645A1 (en) * 1998-11-23 2000-05-23 Pulmonox Medical Corporation Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US20070086954A1 (en) * 1998-11-23 2007-04-19 Miller Christopher C Method and apparatus for treatment of respiratory infections by nitric oxide inhalation
US6261594B1 (en) 1998-11-25 2001-07-17 The University Of Akron Chitosan-based nitric oxide donor compositions
US7516742B2 (en) * 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20050142217A1 (en) * 2000-04-26 2005-06-30 Adams Michael A. Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
EP1278547B1 (en) * 2000-04-26 2004-11-03 Cellegy Pharmaceuticals, Inc Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
US6514193B2 (en) 2000-11-16 2003-02-04 Microspherix Llc Method of administering a therapeutically active substance
EP1545705A4 (en) 2000-11-16 2010-04-28 Microspherix Llc Flexible and/or elastic brachytherapy seed or strand
US6432077B1 (en) * 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7122018B2 (en) * 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
AU2002336761A1 (en) * 2001-09-26 2003-04-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
WO2003050241A2 (en) * 2001-12-12 2003-06-19 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7531133B2 (en) 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
US8501858B2 (en) * 2002-09-12 2013-08-06 Board Of Trustees Of Michigan State University Expanded graphite and products produced therefrom
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
JP2006522021A (en) * 2003-02-03 2006-09-28 パロ アルト インスティチュート オブ モレキュラー メディシン Cellular molecules and methods of use thereof killing
US7362274B1 (en) * 2003-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
EP1653978A1 (en) * 2003-07-09 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of nitrite salts for the treatment of cardiovascular conditions
US20070154570A1 (en) * 2004-09-29 2007-07-05 Miller Christopher C Use of nitric oxide in the treatment and disinfection of biofilms
US7569559B2 (en) * 2004-02-09 2009-08-04 Noxilizer, Inc. Nitric oxide-releasing molecules
JP2007523900A (en) * 2004-02-09 2007-08-23 ノクシライザー,インコーポレイテッドNoxilizer, Incorporated Nitric oxide releasing molecules
AU2005244078A1 (en) 2004-05-11 2005-11-24 Pulmonox Technologies Corporation Intermittent dosing of nitric oxide gas
US8518457B2 (en) * 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
US20080039521A1 (en) * 2004-06-10 2008-02-14 Hiroyasu Yasuda Anticancer Effect Enhancer
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
US8557300B2 (en) * 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US20080241208A1 (en) * 2005-06-30 2008-10-02 Charles Shanley Methods, Compositions and Devices For Promoting Anglogenesis
CA2613106A1 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Analyte sensors and compositions for use therein
JP2008544820A (en) * 2005-06-30 2008-12-11 エムシー3, インコーポレイテッド Nitric oxide coatings for medical devices
US7736293B2 (en) 2005-07-22 2010-06-15 Biocompatibles Uk Limited Implants for use in brachytherapy and other radiation therapy that resist migration and rotation
US8187159B2 (en) 2005-07-22 2012-05-29 Biocompatibles, UK Therapeutic member including a rail used in brachytherapy and other radiation therapy
US20070116785A1 (en) * 2005-11-18 2007-05-24 Miller Christopher C Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
EP1968664B1 (en) * 2005-12-02 2010-10-27 The Regents Of The University Of Michigan Polymer compositions, coatings and devices, and methods of making and using the same
EP1968615A4 (en) * 2005-12-06 2010-08-04 Amulet Pharmaceuticals Inc Nitric oxide-releasing polymers
US8079998B2 (en) * 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
US20080193566A1 (en) * 2007-02-09 2008-08-14 Miller Christopher C Use of high dose concentrations of gaseous nitric oxide
JP2011507968A (en) * 2007-12-27 2011-03-10 エイヤーズ ファーマシューティカルズ、インク. Aerosolized nitrite and nitric oxide donating compounds and the use thereof
EP2340034B2 (en) * 2008-08-07 2019-02-13 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Radioprotectants targeting thrombospondin-1 and cd47
WO2010096766A1 (en) 2009-02-23 2010-08-26 Noxilizer, Inc. Device and method for gas sterilization
BR112012003792A2 (en) 2009-08-21 2016-04-19 Novan Inc topical gel, and use of the topical gel.
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
ES2572803T3 (en) 2010-11-09 2016-06-02 Ironwood Pharmaceuticals, Inc. SGC stimulators
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US9199026B2 (en) * 2011-01-07 2015-12-01 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
ES2695173T3 (en) 2011-02-28 2019-01-02 Novan Inc Silica particles modified with S-nitrosothiol that release nitric oxide and methods of manufacturing them
CN104066731B (en) 2011-12-27 2016-06-15 铁木医药有限公司 Sgc useful as stimulants of 2-benzyl-3- (pyrimidin-2-yl) substituted pyrazoles
WO2013106443A1 (en) 2012-01-09 2013-07-18 Somerset Group Enterprises, Inc. Modular extracorporeal systems and methods for treating blood-borne diseases
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EA201890641A3 (en) 2013-03-15 2018-11-30 Айронвуд Фармасьютикалз, Инк. Sgc stimulators
EA032028B1 (en) 2013-12-11 2019-03-29 Айронвуд Фармасьютикалз, Инк. sGC STIMULATORS
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
WO2016044446A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
EP3194382A1 (en) 2014-09-17 2017-07-26 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
EP3481820A1 (en) 2016-07-07 2019-05-15 Ironwood Pharmaceuticals, Inc. Solid forms of an sgc stimulator
CN109476686A (en) 2016-07-07 2019-03-15 铁木医药有限公司 The phosphorus prodrug of sGC stimulant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
DE69229598T2 (en) * 1991-04-19 1999-11-04 Childrens Medical Center A method for preventing NMDA receptor complex-mediated neuronal damage
AU668107B2 (en) * 1991-09-24 1996-04-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs
US5389675A (en) * 1992-03-27 1995-02-14 The United States Of America As Represented By The Department Of Health And Human Services Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents
WO1993020806A1 (en) * 1992-04-13 1993-10-28 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide/nucleophile complexes for the treatment of cancer
AT194769T (en) * 1993-10-08 2000-08-15 Us Health Use of nitric oxide-releasing compounds as a drug for strahlungssensibilisation for hypoxic cells

Also Published As

Publication number Publication date
US5650442A (en) 1997-07-22
WO1995010267A1 (en) 1995-04-20
AU685178B2 (en) 1998-01-15
AU7967394A (en) 1995-05-04
EP0722320A1 (en) 1996-07-24
CA2173738A1 (en) 1995-04-20
DE69425331D1 (en) 2000-08-24
US5814667A (en) 1998-09-29
US5837736A (en) 1998-11-17
EP0722320B1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
DE69417049D1 (en) Hydroxamic acid derivatives as inhibitors of cylokine production
DE59407626D1 (en) Sulfonylaminopyrimidine, their preparation and use as medicaments
DE59108930D1 (en) , Pharmaceuticals containing these compounds, cyclic imino derivatives and process for their preparation
BR9408051A (en) Microcapsules containing solid biologically active compound and process for preparing microcapsules containing biologically active composite solid
DE69420375T2 (en) Matrix of optical biosensors
NO950009D0 (en) Heterocyclic compounds as pharmaceuticals
AT254594T (en) Compounds useful as intermediates for the preparation of piperidine derivatives
AT150749T (en) Substituted heterocyclic carboxamides, their production and their use as medicines
DE69025473T2 (en) imidazole substituted and their use as hemmmstoff for angiotensin ii
DE60014603D1 (en) Of heterocyclic urea and related compounds as anti-inflammatory agents
AT407362T (en) to changed its screening of compounds for their ability to production of beta-amyloid peptides
DE69635254D1 (en) Ortho-substituted aromatic compounds which contain three (het) aryl rings, their preparation and their use as prostaglandin E2 (PGE2) antagonists
AT179420T (en) Pyrimido (5,4-d&gt; pyrimidine, these drug compounds containing, their use and process for their manufacture
AT126512T (en) N- (aryloxyalkyl) heteroarylpiperidines and - heteroarylpiperazine, methods for their manufacture and their use as medicines.
DE69429822T2 (en) Exfoliating composition of salicylic acid and zwitterionic compounds
DE69306956D1 (en) Catalytic combustion of organic compounds
AT169296T (en) connections aromatic nitro and their metabolites useful tumor agent as anti-virus and anti-
DE69425615D1 (en) Condensed seven- or eight-membered heterocyclic compounds useful as Squaleninhibitoren
EE9700043A (en) Substituted oxazolidinones, processes for their preparation, medicaments containing said compounds and the preparation of medicaments
FI940806A (en) Cyclic derivatives, medicaments containing these compounds and process for their preparation
DE3519280A1 (en) Stilbene derivatives and fungicidal containing these compounds
DE69303032T2 (en) As Sweeteners useful compounds and manufacturing processes hir
NO934562D0 (en) Process for destruction of organic compounds
DE69508434T2 (en) Spiroketalderivate, containing these compositions and their use as medicines
DE59208559D1 (en) , Pharmaceuticals containing these compounds, cyclic urea derivatives and process for their preparation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties